Gates Ventures

Lucy Therapeutics Secures New Funding to Advance New Alzheimer’s and Parkinson’s Treatments

Retrieved on: 
火曜日, 5月 28, 2024
Finance, Pharmaceutical, Professional Services, Mental Health, Philanthropy, Neurology, Genetics, Clinical Trials, Fund Raising, Foundation, Biotechnology, Science, Other Philanthropy, Other Science, Research, Health, Patient, Bangladesh Technical Education Board, Gates Ventures, Investigational New Drug, Senior advisor, Investment, Alzheimer's disease, Doctor of Philosophy, Therapy, IND, Neurodegenerative disease, Disease, Drug development, Parkinson's disease, DSM-IV codes, Rett syndrome, Biomarker, Rett, Pharmaceutical industry

The fresh capital brings LucyTx’s total funding to date to more than $36 million.

Key Points: 
  • The fresh capital brings LucyTx’s total funding to date to more than $36 million.
  • The investments will further the company’s research programs for Alzheimer’s and Parkinson's diseases and continue its development of a novel drug target for Rett syndrome.
  • “To make meaningful progress in developing treatments for complex diseases, we need to embrace non-traditional methods.
  • However, this siloed, genetic-only approach has failed to create impactful medications for complex, neurological diseases – even after decades of research.

Sinaptica Therapeutics Selected for StartUp Health’s Alzheimer’s Moonshot

Retrieved on: 
水曜日, 5月 22, 2024
Neurology, Other Health, Health, Pharmaceutical, Clinical Trials, Patient, Gates Ventures, FDA, Therapy, Disease, Moonshot, Default mode network, Alzheimer's disease, Oxford University Press, Medicine, University of Oxford, Pharmaceutical industry

Sinaptica Therapeutics, Inc ., a clinical-stage company leading the development of a new class of personalized neuromodulation therapeutics to treat Alzheimer’s (AD) and other neurodegenerative diseases, today announced that it has been selected to join StartUp Health’s Alzheimer’s Moonshot .

Key Points: 
  • Sinaptica Therapeutics, Inc ., a clinical-stage company leading the development of a new class of personalized neuromodulation therapeutics to treat Alzheimer’s (AD) and other neurodegenerative diseases, today announced that it has been selected to join StartUp Health’s Alzheimer’s Moonshot .
  • “Sinaptica is honored to be included in this hand-selected group of innovators working to end Alzheimer’s – a goal which we believe will require combinatorial approaches,” said Sinaptica CEO Ken Mariash.
  • “Sinaptica brings a bold new personalized neuromodulation approach that can be combined with virtually any drug, given its near-total lack of side effects.
  • “We created the Alzheimer’s Moonshot to bring together trailblazers, support new approaches and rapidly accelerate progress in this challenging disease.

Luminar Attracts Former Executives From Lyft, Apple and Meta, Microsoft

Retrieved on: 
金曜日, 4月 12, 2024
Software, Vehicle Technology, Hardware, General Automotive, Technology, Automotive, Artificial Intelligence, Public Relations, Investor Relations, Engineering, Marketing, Communications, Automotive Manufacturing, Manufacturing, Electrical engineering, Computer vision, Blog, University, Executive, Safety, Gates Ventures, Meta, Mac Pro, History, Pershing Square Capital Management, IPO, Lyft, Senior, Microsoft, IMac, MacBook, Amazon Fire, Communication, Theology, European, Apple, Lidar, Pershing Square Holdings, Doctorate, Growth, Management

Dr. Foster's extensive experience includes executive and leadership positions at Lyft, Apple, Microsoft, Amazon, and other innovative technology companies.

Key Points: 
  • Dr. Foster's extensive experience includes executive and leadership positions at Lyft, Apple, Microsoft, Amazon, and other innovative technology companies.
  • Dr. Foster holds a BA, MA, and Doctorate in Philosophy in Electrical Engineering and Computer Vision from the University of Oxford.
  • “I am delighted to be joining Luminar at this exciting time for the company and the industry,” said David Foster.
  • “The products in development at Luminar will make a profoundly positive impact on the lives of motorists around the world.

EDAN and GH Labs Collaborate to Develop AI-Enabled Ultrasound Devices

Retrieved on: 
月曜日, 3月 18, 2024
Partnership, Gates Ventures, Artificial intelligence, Prenatal care, Entrepreneurship, AI

BELLEVUE, Wash., March 18, 2024 /PRNewswire/ -- Edan Instruments, Inc. (300206.SZ), a leading global provider of medical and healthcare solutions, announces a collaboration with Global Health Labs, Inc. (GH Labs) to co-develop AI-enabled ultrasound devices.

Key Points: 
  • BELLEVUE, Wash., March 18, 2024 /PRNewswire/ -- Edan Instruments, Inc. (300206.SZ), a leading global provider of medical and healthcare solutions, announces a collaboration with Global Health Labs, Inc. (GH Labs) to co-develop AI-enabled ultrasound devices.
  • Under the agreement signed on March 13, 2024, in Bellevue, Washington, EDAN and GH Labs will combine their expertise to create innovative ultrasound solutions powered by artificial intelligence.
  • "We are excited to embark on this transformative journey with GH Labs," said Xicheng Xie, Co-Founder and Vice President of EDAN.
  • Through this collaboration, GH Labs will provide technical expertise to support the development of AI-enabled ultrasound devices tailored for LMICs.

EDAN and GH Labs Collaborate to Develop AI-Enabled Ultrasound Devices

Retrieved on: 
月曜日, 3月 18, 2024
Partnership, Gates Ventures, Artificial intelligence, Prenatal care, Entrepreneurship, AI

BELLEVUE, Wash., March 18, 2024 /PRNewswire/ -- Edan Instruments, Inc. (300206.SZ), a leading global provider of medical and healthcare solutions, announces a collaboration with Global Health Labs, Inc. (GH Labs) to co-develop AI-enabled ultrasound devices.

Key Points: 
  • BELLEVUE, Wash., March 18, 2024 /PRNewswire/ -- Edan Instruments, Inc. (300206.SZ), a leading global provider of medical and healthcare solutions, announces a collaboration with Global Health Labs, Inc. (GH Labs) to co-develop AI-enabled ultrasound devices.
  • Under the agreement signed on March 13, 2024, in Bellevue, Washington, EDAN and GH Labs will combine their expertise to create innovative ultrasound solutions powered by artificial intelligence.
  • "We are excited to embark on this transformative journey with GH Labs," said Xicheng Xie, Co-Founder and Vice President of EDAN.
  • Through this collaboration, GH Labs will provide technical expertise to support the development of AI-enabled ultrasound devices tailored for LMICs.

New Initiative Launched to Accelerate the Use of AI in the Fight Against Neurodegenerative Diseases

Retrieved on: 
火曜日, 2月 13, 2024
Master of Science, Artificial intelligence, AI, Gates Ventures, Rain, Richard Rainwater, Partnership, Health, SPARC, MBA, Neurodegenerative disease, Business development, King's College London, Prevalence, Patient, Milken Institute, Harvard Business School, Research, Parkinson's disease, Brain, Medical device

OAKLAND, Calif., Feb. 13, 2024 /PRNewswire/ -- The 10,000 Brains Project, an independent 501(c)(3) nonprofit organization, has been launched to promote the ethical use of artificial intelligence (AI) in the fight against Alzheimer's, Parkinson's, and other neurodegenerative diseases. The organization's mission is to provide the leadership, expertise, and financial support needed to ensure that researchers can rapidly adopt this powerful new technology in the search for better diagnostics and treatments for patients in need.

Key Points: 
  • Neurodegeneration is perhaps the most complex challenge in healthcare and the development of treatments has proven resistant to traditional research methods.
  • Patrick Brannelly, a seasoned executive in nonprofit and entrepreneurial ventures, has been named the founding CEO of The 10,000 Brains Project.
  • We are excited to build a research roadmap that will show how private funding can accelerate this important area of medical research."
  • First, solving neurodegenerative diseases will require researchers to recognize the full diversity of human brains; every person's brain is different, and their disorders can take a variety of different paths.

StartUp Health Launches Global Alzheimer's Moonshot with Support from the Alzheimer's Drug Discovery Foundation (ADDF) and Gates Ventures

Retrieved on: 
月曜日, 1月 8, 2024
Fillit, Moon, Entrepreneurship, Conference, Partnership, Learning, Gates Ventures, Research, Eli Lilly, Human, Fellow, MD, SAN, Dual-energy X-ray absorptiometry, Medicine, Biomarker, Growth, Patient, Diagnosis, History, Dementia, Therapy, Pharmaceutical industry

SAN FRANCISCO, Jan. 8, 2024 /PRNewswire-PRWeb/ -- During the 42nd Annual J.P. Morgan Healthcare Conference week, StartUp Health, in partnership with the Alzheimer's Drug Discovery Foundation's (ADDF) Diagnostics Accelerator (DxA), and Gates Ventures, the private office of Bill Gates, announced the launch of the Alzheimer's Moonshot. This initiative aims to break down silos and foster meaningful collaboration between mission-aligned founders, funders, and partners, accelerating progress in preventing, managing, and curing Alzheimer's and related dementias through the support of entrepreneurial innovation. The Alzheimer's Moonshot is an invitation to Health Transformers, Alzheimer's funders, foundations, advocates, and innovators, as well as leading startups and research teams, to unite in pioneering comprehensive, collaborative approaches to Alzheimer's disease.

Key Points: 
  • SAN FRANCISCO, Jan. 8, 2024 /PRNewswire-PRWeb/ -- During the 42nd Annual J.P. Morgan Healthcare Conference week, StartUp Health , in partnership with the Alzheimer's Drug Discovery Foundation 's (ADDF) Diagnostics Accelerator (DxA), and Gates Ventures, the private office of Bill Gates, announced the launch of the Alzheimer's Moonshot.
  • "The ADDF welcomes the opportunity to partner with StartUp Health to launch the Alzheimer's Moonshot," notes Howard Fillit, MD, Co-Founder and Chief Science Officer at the ADDF.
  • Are you an academic founder, founder, startup or research team focused on Alzheimer's innovation who would like to join the Alzheimer's Moonshot?
  • To explore how your organization can become part of the Alzheimer's Moonshot (or one of our 14 global health moonshots) please reach out to us at [email protected] .

Alzheimer's Drug Discovery Foundation (ADDF) Announces Launch of SpeechDx, the First Study to Generate a Voice Database Paired with Clinical Data for Early Detection of Alzheimer's Disease

Retrieved on: 
月曜日, 10月 23, 2023
Fillit, Intelligence, Speech, Alzheimer's Drug Discovery Foundation, Neuroimaging, Biomarker, Gates Ventures, Human, Data, MD, Health, Doctor of Philosophy, Entrepreneurship, Dementia, Research, Tablet, BBRC, Disease, Ace, Machine learning, Emory University, Boston University, Brain, Algorithm, Language, Collection, Diagnosis, Dual-energy X-ray absorptiometry, Pharmaceutical industry, Medical imaging, Mobile phone, Alzheimer's disease

NEW YORK, Oct. 23, 2023 /PRNewswire/ -- The Alzheimer's Drug Discovery Foundation's (ADDF) Diagnostic Accelerator (DxA) today announced the launch of SpeechDx, the first longitudinal study aimed at creating the largest repository of speech and voice data to help accelerate the detection, diagnosis and monitoring of Alzheimer's disease. Recorded voice samples from the study will be paired with clinical and biomarker data that can be leveraged by academic, biotech, and industry partners to develop algorithms for the creation of new speech biomarkers.

Key Points: 
  • SpeechDx is poised to develop a paired voice and clinical database that will provide the research community with harmonized data needed to generate speech-based diagnostic algorithms.
  • Study participants will be given handheld tablets with the pre-installed SpeechDx app to capture their voice data.
  • The use of this warehouse of data will be fundamental for the development of new and renewable digital voice biomarkers.
  • Additionally, each participant's voice recording will be paired with clinical data and harmonized across all sites.

Revolutionizing Alzheimer's Prevention and Treatment: The Alzheimer's Drug Discovery Foundation and the FINGERS Brain Health Institute Announce Precision Prevention Partnership

Retrieved on: 
水曜日, 10月 4, 2023
Fillit, Karolinska Institute, Medicine, Partnership, Drug development, Therapy, Senior, Prevalence, Diabetes, AARP, Alzheimer's Drug Discovery Foundation, Health, Cancer, Ageing, Brain, Risk, Biomarker, Inflammation, Doctor of Philosophy, Dementia, Organization, Incidence, Science, Physician, Patient, Drug discovery, Biology, Metformin, Gates Ventures, Entrepreneurship, FDA, Geriatrics, Disease, Pharmaceutical industry, Medical imaging, Alzheimer's disease, MD, Policy

NEW YORK, Oct. 4, 2023 /PRNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) and the FINGERS Brain Health Institute (FBHI) announced today a new Precision Prevention Partnership, a unique collaboration set to transform the landscape of Alzheimer's disease prevention and treatment. Together, the ADDF and the FBHI will advance physicians' ability to tailor precision prevention approaches that combine lifestyle interventions and therapeutics to help delay or prevent the onset of the disease based on patients' individual risk and biomarker profiles.

Key Points: 
  • Alzheimer's is a complex disease, and a one size fits all approach will not effectively treat its varied causes and forms."
  • "With this new collaboration, our two organizations will redefine the prevention landscape by targeting several risk factors simultaneously to get optimal preventive effects against Alzheimer's disease."
  • This model will serve as a template for the next generation of combination clinical trials, helping to speed up the drug development pipeline.
  • Accelerating the development of new biomarkers for aging, helping improve Alzheimer's diagnostics and aiding in the development of novel drugs.

New NEURii Research Collaboration Between Eisai, Gates Ventures, Health Data Research UK, Lifearc and The University of Edinburgh to Develop Digital Solutions for Dementia is Announced

Retrieved on: 
金曜日, 6月 30, 2023
Pressure, Maintenance, LifeArc, Partnership, University, Therapy, Life, Doctor of Philosophy, Speech, Public, Neurodegenerative disease, University of Edinburgh, Health, Ageing, Alzheimer's Research UK, Quality of life, ML, Research, Genomics, Biomarker, Mentorship, HDR, Disorder, Dementia, Alzheimer's disease, Digital technology, HIV disease progression rates, Patient, Orangi Pilot Project, Machine learning, Algorithm, Artificial intelligence, Drug discovery, Gates Ventures, Diagnosis, AI, Neurology, Disease, Pharmaceutical industry, Industrial design, Medical device, Nursing, Eisai

- NEURii collaboration builds on Eisai's extensive experience in delivering innovative treatments in neurology and supports ongoing contributions to the global digital health ecosystem.

Key Points: 
  • - NEURii collaboration builds on Eisai's extensive experience in delivering innovative treatments in neurology and supports ongoing contributions to the global digital health ecosystem.
  • TOKYO, HATFIELD, SEATTLE, LONDON, and EDINBURGH, June 30, 2023 - (JCN Newswire) - Eisai, Gates Ventures, Health Data Research UK (HDR UK), LifeArc and The University of Edinburgh announced today a new two-year collaborative research agreement.
  • NEURii will focus its initial efforts to develop data and digital solutions to complement approved treatment options for patients and solve issues related to the prediction, prevention, management, and treatment of dementia related disorders.
  • It is envisaged that NEURii partners will explore further opportunities to scale up the program developing digital health solutions worldwide.